Understanding Xarelto 15 Bayer
Xarelto 15 Bayer is a pharmaceutical-grade rivaroxaban formulation manufactured by Bayer Pharmaceuticals. Rivaroxaban is a factor Xa inhibitor belonging to the direct oral anticoagulant (DOAC) class of compounds. This pharmaceutical preparation contains rivaroxaban as the active ingredient at 15mg concentration per tablet, formulated according to European Pharmacopoeia standards. The compound demonstrates high bioavailability and predictable pharmacokinetics in preclinical models, making it valuable for cardiovascular and haematological research studies. Researchers studying anticoagulation mechanisms, coagulation cascade inhibition, and thrombosis prevention pathways will find this pharmaceutical reference standard particularly useful for comparative analysis. The preparation meets pharmaceutical manufacturing standards and provides researchers with access to a clinically-validated compound for laboratory investigations. For comprehensive research chemical supplies, visit our main Stroid UK Shop to explore our full catalogue of research compounds.
Research Applications
Rivaroxaban research focuses primarily on its mechanism as a direct factor Xa inhibitor within the coagulation cascade. In laboratory studies, researchers examine its binding affinity to the active site of factor Xa, preventing the conversion of prothrombin to thrombin. This mechanism provides valuable insights into anticoagulation pathways and thrombin generation inhibition. Cardiovascular research laboratories utilise rivaroxaban to investigate venous thromboembolism prevention mechanisms and arterial thrombosis models. The compound’s oral bioavailability and rapid onset of action make it suitable for pharmacokinetic studies examining absorption, distribution, and elimination patterns. Haematology researchers examine its effects on various coagulation parameters including prothrombin time, activated partial thromboplastin time, and anti-factor Xa activity levels. Studies also investigate drug-drug interactions, particularly with P-glycoprotein inhibitors and CYP3A4 modulators. For related research compounds, explore our general research category, SARMs collection, or peptides section for comprehensive research options.
Technical Specifications
| Parameter | Specification |
|---|---|
| Active Ingredient | Rivaroxaban 15mg |
| CAS Number | 366789-02-8 |
| Molecular Formula | C₁₉H₁₈ClN₃O₅S |
| Molecular Weight | 435.89 g/mol |
| Manufacturer | Bayer Pharmaceuticals |
| Form | Film-coated tablets |
| Storage Conditions | Room temperature, dry environment |
| Shelf Life | As per manufacturer specifications |
Research Compliance Information
This Xarelto 15 Bayer preparation is supplied exclusively for in-vitro research applications and analytical testing purposes. The product is intended for qualified research laboratories conducting studies on anticoagulation mechanisms, coagulation cascade pathways, and pharmaceutical analysis. Researchers must ensure appropriate laboratory safety protocols and disposal procedures for pharmaceutical compounds. This preparation is not intended for human consumption, clinical use, or any application outside controlled laboratory environments. All research activities must comply with institutional guidelines and relevant pharmaceutical research regulations. Storage should follow standard pharmaceutical storage conditions to maintain compound stability and integrity throughout the research period.
